Navigation Links
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease
Date:11/10/2008

understanding of cysteamine's effects in Huntington's patients and we hope it may lead to a new treatment for this serious, debilitating disease."

The primary endpoint of the Phase II trial will be evaluated using the Unified Hungtington's Disease Rating Scale ("UHDRS"). The secondary endpoint will measure brain-derived neurotrophic factor ("BDNF") levels, known to be deficient in Huntington's patients. A preclinical study published by Drs. Sandrine Humbert and Frederic Saudou from the Curie Institute demonstrated a potential mechanism for cysteamine in an in vivo preclinical Huntington's model that showed increased brain and blood levels of BDNF. The Curie Institute will participate in the clinical trial by determining the BDNF levels in the patients.

About Huntington's Disease

Huntington's is a rare, progressive, and hereditary neurological disease that often leads to death within 15 to 20 years after diagnosis. The disease is thought to affect as many as 20,000 patients in the U.S. There is no currently available drug that targets the defective gene believed to cause Huntington's, which results in the degeneration of certain nerve cells in the brain. The disease is characterized by uncontrollable movements and mood swings or depression, followed by dementia.

About Cysteamine and DR Cysteamine

Cysteamine is approved for sale by the FDA and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare, genetic lysosomal storage disease. DR Cysteamine is designed as an enterically coated, proprietary oral formulation of cysteamine to potentially reduce dosing frequency and gastrointestinal side effects.

Raptor obtained an exclusive, worldwide license from the University of California, San Diego ("UCSD") for the development of cysteamine and DR Cysteamine for a number of potential indications including Huntington's, cystinosis, non-alcoholic steatohepatitis ("NASH") and Batten Disease. Raptor is
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update on Targeting Platforms
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  The Pittsburgh Life Sciences Greenhouse (PLSG), the region,s ... one of its portfolio companies, Medrobotics Corporation, has received ... Robotic System in the U.S.  "I ... said John W. Manzetti , president and CEO ... since spinning out of The Robotics Institute at Carnegie ...
(Date:8/4/2015)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at ... in New York . A live webcast ... A replay will be available approximately one hour after the ...
(Date:8/4/2015)... , Aug. 4, 2015  Armada ... of Massachusetts Medical School,s Clinical Pharmacy Services ... regarding clinical protocols and therapy interventions within ... Specialty medication therapy management is ... to ensure optimal patient outcomes are achieved ...
Breaking Medicine Technology:Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3
... LAKE FOREST, Ill., May 24, 2012   Hospira, ... leading provider of injectable drugs and infusion technologies, ... of I.V. clinical integration of infusion pumps and ... Technology Management Week, which recognizes the important work ...
... England and MILAN, May 24, 2012 Mylan Inc. (Nasdaq: ... Italy-based subsidiaries have launched Ibandronic Acid Film Coated Tablets POM, ... ® Tablets, a treatment for osteoporosis(1). ... generic for Mylan,s businesses in the UK and Italy. We ...
Cached Medicine Technology:I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process 2I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process 3Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy 2
(Date:8/4/2015)... ... August 04, 2015 , ... ... whose cancer has come back: Retreatment may be a viable option. Surviving Mesothelioma ... it now. , According to surgeons at the University of New South ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and other long-term care facilities, today announced details of the Advanced level of ... and centers. , Providigm’s QAPI Accreditation program , introduced in 2013, is ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... finds the North America IT reseller channel will grow at least 6 percent ... of their 2014 pace and greater than their OEM/vendor partners. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may decline ... driving, says the August 2015 Harvard Health Letter. , "Age and health conditions ... an individual assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated ...
(Date:8/4/2015)... ... August 04, 2015 , ... Updated enrollment data on the top U.S. health ... be accessed at http://www.AISHealth.com . The data is free to all registered users ... tables and charts on the website’s “Data” section include:, , ...
Breaking Medicine News(10 mins):Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2
... in West Virginia to control obesity in children. The public schools ... a large scale. The game // involves a player moving his/her ... screen. Children aged between 10 years and 14 years will be ... ,West Virginia has turned to computer games to make school children ...
... Wall Street Journal studied about the effects of stress on the pregnant ... number of researches is being conducted on stress and people are in ... ,There is an increase in the number of pregnant women approaching ... ,Hence there is a need to include new ...
... out to be negative for the presence of Japanese ... the health minister Datuk Dr Chua Soi Lek. The ... ,The victim, Norhayati Awang is currently being ... Perempuan Zainab II. According to official reports, she is ...
... by Australian researchers could pave way for an improvement in ... of lung cancer with a high mortality rate. The promising ... definitive diagnosis of lung cancer. ,The study participants were ... rate for these patients was projected to be less than ...
... Food and Drug Administration (FDA) against the seafood processing ... // This will effectively stop the company from ... fish is reported to be contaminated, as a result ... ,The inspections conducted by the FDA in 2004 ...
... Madras Institute of Trauma, more familiarly known as MIOT ... system of a city in Germany, aimed at sharing ... ,MIOT signed a memorandum of understanding ... Stuttgart's public healthcare system is entering into such a ...
Cached Medicine News:Health News:New Treatment Offers Hope For Lung Cancer Patients 2
... The Ray TFC Unite Device is the ... The Ray TFC Unite device features the same ... contact offered by fenestrations is paramount in the ... the Ray TFC Unite system promotes load sharing ...
... The INTER FIX and ... Devices are designed to maximize ... of the implant. Both the ... RP Threaded Fusion devices combine ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
Medicine Products: